A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

A Randomized, Double-blind, First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

The purpose of this study is to assess the safety and tolerability of 2 single doses of either 5*10^10 viral particles (vp) or 1*10^11 vp of Ad26.RSV.preF, administered intramuscularly to elderly adults given approximately 12 months apart.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Biological: Ad26.RSV.preF 5*10^10 vp; Drug: Placebo; Biological: Ad26.RSV.preF 1*10^11 vp

• Study Type: Interventional
• Enrollment (Actual): 73
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Miami, Florida, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Each participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study, is willing to participate in the study and attend all scheduled visits, and is willing and able to comply with all study procedures and adhere to the prohibitions and restrictions specified in this protocol
• Before randomization, a woman must be: postmenopausal - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause; and not intending to conceive by any methods
• From the time of first vaccination until 3 months after the first dose of study vaccine, and from the second vaccination through 3 months after, a man who has not had a vasectomy (or if a vasectomy was performed less than 1 year ago and the absence of sperm cannot be verified)
• In the investigator's clinical judgment, participant must be either in good or stable health. Participants may have underlying illnesses such as hypertension, type 2 diabetes, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms/signs are medically controlled. If they are on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study. Participants will be included on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening
• Participant must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the laboratory screening tests are outside the central laboratory normal reference ranges and additionally within the limits of toxicity Grades 1 or 2 according to the US Food and Drug Administration (FDA) toxicity tables (for tests in the FDA table ), the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant and appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator

Exclusion Criteria:

• Participant has acute illness (this does not include minor illnesses such as diarrhea) or temperature greater than or equal to (>=) 38.0 degree celsius within 24 hours prior to the first dose of study vaccine; enrollment at a later date is permitted
• Participant has a serious chronic disorder, including severe chronic obstructive pulmonary disease or clinically significant congestive heart failure, requirement for supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, Alzheimer's disease, or has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments
• Participant has had major surgery within the 4 weeks prior to randomization or has planned major surgery through the course of the study
• Participant has chronic active hepatitis B or hepatitis C infection, documented by hepatitis B surface antigen and hepatitis C antibody, respectively
• Participant has human immunodeficiency virus (HIV) type 1 or type 2 infection

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ad26.RSV.preF 5*10^10 vp (Day 1 and Day 365): Group 1; Participants will receive 5*10^10 viral particles (vp) Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).	Biological: Ad26.RSV.preF 5*10^10 vp; Ad26.RSV.preF will be given at a concentration of 5*10^10 vp/0.5 milliliter (mL).; Other Names: JNJ-64400141
Experimental: Ad26.RSV.preF 5*10^10 vp (Day 1)- Placebo (Day 365): Group 2; Participants will receive 5*10^10 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).	Biological: Ad26.RSV.preF 5*10^10 vp; Ad26.RSV.preF will be given at a concentration of 5*10^10 vp/0.5 milliliter (mL).; Other Names: JNJ-64400141; Drug: Placebo; Participants will receive placebo as formulation buffer.
Experimental: Ad26.RSV.preF 1*10^11 vp (Day 1 and Day 365): Group 3; Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).	Biological: Ad26.RSV.preF 1*10^11 vp; Ad26.RSV.preF will be given at a concentration of 1*10^11 vp/0.5 milliliter (mL).; Other Names: JNJ-64400141
Experimental: Ad26.RSV.preF 1*10^11 vp (Day 1)- Placebo (Day 365): Group 4; Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).	Drug: Placebo; Participants will receive placebo as formulation buffer.; Biological: Ad26.RSV.preF 1*10^11 vp; Ad26.RSV.preF will be given at a concentration of 1*10^11 vp/0.5 milliliter (mL).; Other Names: JNJ-64400141
Experimental: Placebo (Day 1 and Day 365): Group 5; Participants will receive placebo at Day 1 and Day 365 (10 to 13 months after first vaccination).	Drug: Placebo; Participants will receive placebo as formulation buffer.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination (Day 1)	7 days after each vaccination (Day 1)
Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination (Day 365)	7 days after each vaccination (Day 365)
Number of Participants With Solicited Systemic Adverse Events (AEs) for 7 Days After Each Vaccination (Day 1)	7 days after each vaccination (Day 1)
Number of Participants With Solicited Systemic Adverse Events (AEs) for 7 Days After Each Vaccination (Day 365)	7 days after each vaccination (Day 365)
Number of Participants With Unsolicited AEs for 28 Days After Each Vaccination	28 days after each vaccination (from signing the informed consent form [ICF] to Day 29 inclusive)
Number of Participants With Serious Adverse Events (SAEs) Throughout Study	Up to 730 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Respiratory Syncytial Virus (RSV) Neutralization A2	Analysis of RSV A2 neutralizing titers of the vaccine-induced immune response will be assessed.	Days 1, 29, 183, 365, 393, 547, 730
RSV Fusion Protein (F-protein) Enzyme-linked Immunosorbent Assay	Analysis of antibodies binding to RSV F protein in post-fusion and pre-fusion form.	Days 1, 29, 183, 365, 393, 547, 730
Intracellular Cytokine Staining	The activation of cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T-cell subsets and their cytokine expression patterns will be determined by flow cytometry after RSV protein peptide stimulation (including, but not limited to CD4/CD8, interleukin [IL-2], interferon gamma [IFN gamma], tumor necrosis factor alpha [TNF-alpha] and/or activation markers, memory, T-helper [cells] Th1/Th2 subtyping).	Day 1, 29, 183, 365, 393, 547, 730

Collaborators and Investigators

• Sponsor: Janssen Vaccines & Prevention B.V.

Study record dates

Study Major Dates

• Study Start (Actual): November 8, 2016
• Primary Completion (Actual): March 14, 2018
• Study Completion (Actual): January 29, 2019

Study Registration Dates

• First Submitted: September 22, 2016
• First Submitted That Met QC Criteria: October 5, 2016
• First Posted (Estimate): October 6, 2016

Study Record Updates

• Last Update Posted (Actual): February 19, 2019
• Last Update Submitted That Met QC Criteria: February 18, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Other Study ID Numbers: CR108214; VAC18193RSV1003 (Other Identifier: Janssen Vaccines & Prevention B.V.)

Drug and device information, study documents

• Studies a U.S. FDA-regulated device product: No